成大生物(688739) - 2025 Q4 - 年度业绩
2026-02-27 07:50
Financial Performance - Total revenue for 2025 was RMB 139,028.74 million, a decrease of 17.06% compared to the previous year[4] - Net profit attributable to shareholders of the parent company was RMB 13,761.67 million, down 59.86% year-on-year[4] - Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was RMB 4,599.98 million, a decline of 85.79%[4] - Basic earnings per share decreased to RMB 0.33, down 60.24% from the previous year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 975,181.82 million, a decrease of 2.98% from the beginning of the period[5] - Equity attributable to shareholders of the parent company was RMB 935,998.52 million, down 2.12% from the beginning of the period[5] Market and Operational Factors - The decline in revenue was primarily due to changes in the domestic rabies vaccine market environment and increased competition[5] - Increased asset impairment losses were due to the termination of the hib vaccine project and full impairment of capitalized R&D investments[5] - The company experienced growth in overseas sales revenue and managed to control selling and administrative expenses effectively[5] Financial Data Disclaimer - Investors are advised to note that the financial data is preliminary and subject to final confirmation in the annual report[7]
唯捷创芯(688153) - 2025 Q4 - 年度业绩
2026-02-27 07:50
Financial Performance - Total revenue for 2025 reached RMB 232,096.23 million, a year-on-year increase of 10.36%[3] - Operating profit was RMB 1,816.24 million, a significant turnaround from a loss of RMB 3,275.63 million in the previous year[3] - Net profit attributable to shareholders of the parent company was RMB 4,494.93 million, compared to a loss of RMB 2,372.51 million in the previous year[3] - Basic earnings per share improved to RMB 0.10 from a loss of RMB 0.06 per share in the previous year[3] - The weighted average return on net assets increased to 1.13%, up by 1.72 percentage points year-on-year[3] Sales and Growth Drivers - The company experienced significant sales growth driven by high-integration modules, particularly in automotive and emerging sectors[6] - New growth points were identified through diversification into AI edge devices, smart robotics, and vehicle communication[7] - The revenue share of high-margin products, such as automotive-grade products and Wi-Fi modules, significantly increased, enhancing overall profitability[7] Assets and Equity - Total assets at the end of the reporting period were RMB 473,051.10 million, reflecting a 3.06% increase from the beginning of the period[4] - Shareholders' equity attributable to the parent company was RMB 402,468.07 million, a slight increase of 0.82%[4]
科美诊断(688468) - 2025 Q4 - 年度业绩
2026-02-27 07:50
Financial Performance - Total revenue for 2025 was CNY 332.68 million, a decrease of 23.75% compared to the previous year[2] - Net profit attributable to shareholders was CNY 44.41 million, down 65.05% year-over-year[2] - The net profit excluding non-recurring gains and losses was CNY 28.15 million, a decline of 72.06% from the previous year[2] - Basic earnings per share decreased by 65.63% to CNY 0.11[2] - Total assets at the end of the reporting period were CNY 1,761.59 million, a decrease of 3.85% from the beginning of the period[2] - Shareholders' equity attributable to the parent company was CNY 1,411.39 million, down 0.35%[2] - The financial data presented is preliminary and unaudited, with the final results to be confirmed in the annual report[6] Market Challenges - The company faced pressure on product prices due to the deep implementation of centralized procurement in the in vitro diagnostics industry[4] Strategic Initiatives - The company maintained high R&D investment to enhance core competitiveness despite the decline in revenue[4] - The company aims to continue its innovation-driven development path and strengthen cost management to adapt to industry changes[5]
映翰通(688080) - 2025 Q4 - 年度业绩
2026-02-27 07:50
Financial Performance - The company achieved total operating revenue of 777.21 million yuan, a year-on-year increase of 27.05%[3] - Operating profit reached 178.82 million yuan, reflecting a growth of 18.04% compared to the previous year[3] - Net profit attributable to shareholders of the parent company was 150.29 million yuan, up 15.71% year-on-year[3] - Basic earnings per share were 2.04 yuan, representing a 15.91% increase[3] - The weighted average return on net assets was 13.73%, an increase of 0.38 percentage points[3] Assets and Equity - The total assets of the company at the end of the reporting period were 1,382.08 million yuan, an increase of 6.98%[7] - The equity attributable to shareholders of the parent company was 1,170.20 million yuan, growing by 12.21%[7] Product Sales Growth - Sales of industrial IoT products increased by 42.11%, while enterprise network products grew by 21.37%[7] - Sales of intelligent vending control system products surged by 224.27%[7] Financial Data Disclaimer - The company warns that the financial data is preliminary and subject to change upon final audit[9]
宣泰医药(688247) - 2025 Q4 - 年度业绩
2026-02-27 07:50
Financial Performance - Total revenue for 2025 was CNY 446.50 million, a decrease of 12.73% compared to the previous year[3] - Net profit attributable to shareholders was CNY 48.95 million, down 61.67% year-on-year[5] - Net profit excluding non-recurring gains and losses decreased by 72.47% to CNY 31.38 million[5] - Basic earnings per share fell by 60.65% to CNY 0.11[3] - The weighted average return on net assets decreased by 6.56 percentage points to 3.81%[3] Assets and Equity - Total assets at the end of the reporting period were CNY 1,437.68 million, a decline of 1.07%[5] - Shareholders' equity attributable to the parent company increased by 1.61% to CNY 1,293.45 million[5] Factors Affecting Performance - The decline in revenue and profit was primarily due to price reductions from national drug procurement policies and increased competition in overseas markets[6] - The company recognized impairment losses on receivables, inventory, and goodwill, negatively impacting net profit[6] Audit and Investment Risks - The financial data presented is preliminary and subject to final audit, highlighting potential investment risks[9]
海天瑞声(688787) - 2025 Q4 - 年度业绩
2026-02-27 07:50
Financial Performance - The company achieved total operating revenue of 376.97 million yuan, a 59.00% increase compared to the same period last year[1] - Net profit attributable to the parent company was 14.07 million yuan, representing a 24.16% year-on-year increase[1] - Net profit attributable to the parent company after deducting non-recurring gains and losses increased by 124.52% to 11.17 million yuan[1] - Operating profit rose by 42.00% to 15.09 million yuan, driven by significant revenue growth[8] - The company's weighted average return on equity increased by 0.41 percentage points to 1.90%[1] Asset Growth - Total assets at the end of the reporting period were 861.75 million yuan, an increase of 6.59% from the beginning of the period[2] Business Development - The visual data business revenue grew over 200%, while text business revenue increased over 100%[3] - The Southeast Asia data delivery system has entered a mature operational phase, contributing significantly to overseas revenue[4] - The company is expanding into downstream applications, successfully developing digital human projects and voice model platforms[4] - The company is actively building specialized data sets for various regions, which are expected to become new growth areas[4]
福立旺(688678) - 2025 Q4 - 年度业绩
2026-02-27 07:50
证券代码:688678 证券简称:福立旺 公告编号:2026-022 福立旺精密机电(中国)股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据,未经会计师事务所审 计,具体数据以公司2025年年度的定期报告为准,提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位:万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅 | | --- | --- | --- | --- | | | | | 度(%) | | 营业总收入 | 197,218.76 | 128,518.14 | 53.46 | | 营业利润 | 4,422.61 | 4,085.03 | 8.26 | | 利润总额 | 4,407.54 | 4,088.74 | 7.80 | | 归属于母公司所有者的净利润 | 5,522.08 | 5,452.60 | 1.27 | | 归属于母公司所有者的扣除非 经常性损益的净利润 | 4,611.56 | 3,85 ...
博众精工(688097) - 2025 Q4 - 年度业绩
2026-02-27 07:50
博众精工科技股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 本公告所载 2025 年度主要财务数据为初步核算数据,未经会计师事务所审计,具 体数据以博众精工科技股份有限公司(以下简称"公司")2025 年年度报告为准,提 请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位:人民币 万元 项目 本报告期 上年同期 增 减 变 动 幅 度(%) 营业总收入 657,062.52 495,420.15 32.63 营业利润 62,659.99 41,851.11 49.72 利润总额 62,017.22 42,022.71 47.58 归属于母公司所有者的净利润 59,133.99 39,839.35 48.43 归属于母公司所有者的扣除非经常性损 益的净利润 33,491.21 31,884.40 5.04 基本每股收益(元) 1.322 0.892 48.21 加权平均净资产收益率(%) 12.66 9.20 3.46 本报告期末 本报告期初 增减变动幅 度(%) 总 资 ...
浩辰软件(688657) - 2025 Q4 - 年度业绩
2026-02-27 07:50
Financial Performance - The company achieved total operating revenue of RMB 33,135.00 million, an increase of 14.64% compared to RMB 28,904.35 million in the previous year[4] - Net profit attributable to the parent company was RMB 5,017.08 million, representing a decrease of 20.36% from RMB 6,299.91 million year-on-year[4] - The basic earnings per share decreased by 19.79% to RMB 0.77 from RMB 0.96 in the previous year[4] - The company reported a decrease of 23.06% in net profit after deducting non-recurring gains and losses, amounting to RMB 4,171.17 million compared to RMB 5,421.37 million in the previous year[4] Assets and Growth - Total assets at the end of the reporting period were RMB 154,911.21 million, a growth of 2.52% from RMB 151,101.37 million at the beginning of the period[4] Business Strategy - The company focused on both domestic and international CAD software business growth, with significant performance improvements in both areas[6] - The net profit margin for the parent company was 15.14%, indicating a focus on global development and product line expansion[7] - The company has increased its marketing expenses to enhance brand promotion and support new product launches[7] - The company is actively pursuing external growth opportunities to solidify its long-term development foundation[7] - The company has successfully transitioned its European operations from product distribution to comprehensive brand marketing, contributing to overseas revenue growth[6]
东方生物(688298) - 2025 Q4 - 年度业绩
2026-02-27 07:50
Financial Performance - Total revenue for 2025 reached RMB 95,899.40 million, an increase of 15.83% compared to the previous year [4] - Operating profit was RMB -57,582.18 million, showing a slight improvement of 0.52% year-on-year [4] - Net profit attributable to shareholders of the parent company was RMB -56,361.90 million, a decrease of 6.54% from the previous year [4] - Basic earnings per share were RMB -2.93, down 8.92% compared to the previous year [4] Assets and Equity - Total assets at the end of 2025 were RMB 720,012.62 million, a decline of 11.05% from the beginning of the year [6] - Shareholders' equity attributable to the parent company was RMB 600,253.83 million, down 9.67% from the beginning of the year [6] - The company reported a decrease in net assets per share to RMB 29.77, down 9.67% from the beginning of the year [6] Return on Investment - The weighted average return on net assets was -8.90%, a decrease of 1.36 percentage points year-on-year [4] Factors Affecting Performance - The decline in net profit was attributed to significant investments in technology platform development, foreign exchange losses, and reduced interest income [7] Financial Data Disclaimer - Investors are advised to note that the financial data is preliminary and subject to final audit, with potential discrepancies in the annual report [8]